Custom Solutions:
From Bench to Market™

The Preferred CDMO for
Pharmaceutical Development
and Manufacturing
LEARN MORE

Enteris BioPharma, Inc. is a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH) offering total integrated CMC and CDMO service support including pre-formulation, proprietary and non-proprietary formulation development, analytical research and development, quality assurance, and cGMP clinical and commercial manufacturing of pharmaceutical dosage forms.

Enteris BioPharma’s proprietary drug delivery technologies include Peptelligence® and ProPerma® which are the subject of numerous feasibility studies and active development programs, several of which are in late-stage clinical development. Enteris BioPharma’s new purpose-built, state-of-the-art facility equipped to handle myriad active pharmaceutical ingredients (APIs), including dedicated processing and containment areas for high potency active pharmaceutical ingredients (HPAPIs).

Additionally, Enteris BioPharma is advancing an innovative internal product pipeline of oral tablet reformulations of drug products that address significant treatment opportunities for which there is no oral delivery option. Enteris BioPharma’s most advanced internal product candidate, Ovarest® (oral leuprolide tablet), is an oral peptide being developed for the treatment endocrine disorders. Tobrate™ (oral tobramycin tablet) is also being developed by Enteris BioPharma for the treatment of uncomplicated urinary tract infection (uUTI).

CDMO Service

Enteris Biopharma CDMO operations are housed within a 32,000-square-foot (2,970 square meters), FDA-inspected and cGMP-compliant facility in northern New Jersey.

LEARN MORE

PEPTELLIGENCE® & PROPERMA®

Enteris BioPharma is the preferred partner in the oral drug delivery of BCS Class III and Class IV compounds, including peptides, peptidomimetics, and small molecules in an enteric-coated tablet.

LEARN MORE

PARTNERSHIPS

Enteris BioPharma builds long-term relationships, with proven novel formulation technology solutions and manufacturing services.

LEARN MORE

PIPELINE

Enteris BioPharma internal pipeline of products are being clinically evaluated and include Ovarest® for several treatments including orphan indications and Tobrate for uUTIs.

LEARN MORE

ABOUT US

Enteris BioPharma is an independent, wholly-owned subsidiary of SWK Holdings Corporation, a publically traded company (Nasdaq: SWKH) and offers innovative formulation solutions and manufacturing services. Enteris has access to capital and resources that it can direct towards expansion and growth opportunities.

LEARN MORE

KNOWLEDGE CENTER

Expand your knowledge. The Enteris BioPharma Knowledge Center is a library of educational tools.

LEARN MORE

KNOWLEDGE CENTER

Expand your knowledge. The Enteris BioPharma Knowledge Center is a library of educational tools.

LEARN MORE
 

CONTACT US